Medtronic stock trades steadily as diabetes and cardiovascular businesses support earnings

Medtronic plc (ISIN IE00BTN1Y115) is a global medical technology company listed on the New York Stock Exchange, and Medtronic stock continues to be driven by its diversified portfolio in cardiovascular, neuroscience and diabetes devices. In its fiscal 2025 third quarter, Medtronic reported revenue of about $8.6 billion, showing mid single digit growth versus the prior year period, according to the company’s latest earnings communication as of 20 February 2025. The combination of relatively stable top line growth, ongoing restructuring efforts and investments in diabetes technology remains central to how Medtronic stock is being evaluated by market participants.

Revenue up mid single digits

In Medtronic’s fiscal 2025 third quarter, total revenue of around $8.6 billion represented growth of roughly 5% compared with the same quarter of fiscal 2024, based on management’s reported figures in its earnings materials dated 20 February 2025. The increase was supported by strength in cardiovascular and neuroscience segments, which together accounted for a significant portion of the company’s sales. Cardiovascular revenue in the quarter was reported at approximately $3.3 billion, up about 4% year on year, while neuroscience revenue reached near $2.3 billion, with growth close to 6% versus the earlier period according to Medtronic’s segment disclosure.

Diabetes revenue provided another focal point for Medtronic stock, as the company continues to build out its insulin pump and continuous glucose monitoring franchises. In fiscal 2025 third quarter, the diabetes segment generated around $700 million in revenue, rising roughly 10% compared with the prior year quarter, supported by new product introductions and geographic expansion. That double digit diabetes growth stands out against the more moderate increases in other segments and gives investors a clear view of where Medtronic is aiming for faster expansion.

Operating margin and EPS performance

Beyond revenue, profitability metrics are important for assessing Medtronic stock. In the same fiscal 2025 third quarter, Medtronic’s operating margin was reported at approximately 21%, slightly higher than the roughly 20% margin recorded in fiscal 2024 third quarter, according to management’s commentary in its earnings materials. That roughly 1 percentage point margin improvement reflects a mix of cost controls, portfolio optimization and scale benefits from higher revenue.

On the bottom line, Medtronic delivered diluted earnings per share (EPS) of about $1.46 in the quarter, representing growth of roughly 8% compared with diluted EPS of around $1.35 in the prior year period. The EPS outcome was attributed to revenue growth, margin expansion and disciplined expense management. For many investors, the fact that EPS growth slightly outpaced revenue growth suggests some positive operating leverage in Medtronic’s model, although the absolute level of margin remains an area of ongoing attention given competitive pressures and regulatory demands in healthcare technology.

Cash generation also forms part of the picture for Medtronic stock. In the first nine months of fiscal 2025, the company reported free cash flow in the range of $5.5 billion, compared with roughly $5.0 billion in the same period of fiscal 2024, indicating an increase of around 10%. That improvement in free cash flow provides support for capital allocation priorities such as dividends, selective share repurchases and continued investment in research and development.

Guidance and long term positioning

Medtronic’s management has offered guidance for full fiscal 2025 that frames investor expectations. For the full fiscal year, the company has guided to revenue growth in the mid single digit range, driven by ongoing momentum in cardiovascular, neuroscience and diabetes businesses. This outlook implies full year revenue of roughly $34 billion to $35 billion if those growth assumptions are realized, based on extrapolations from reported quarters and management commentary.

On earnings, Medtronic’s fiscal 2025 guidance suggests adjusted EPS in a band around $5.60 to $5.70, representing mid to high single digit growth compared with the prior fiscal year’s adjusted EPS of approximately $5.20. The guidance reflects expectations for continued margin discipline, offset by investments in innovation and potential pricing and reimbursement challenges in key markets. For investors following Medtronic stock, how the company navigates that balance between growth and profitability is a central question.

Medtronic’s cardiovascular business, encompassing products such as cardiac rhythm management devices, structural heart solutions and peripheral vascular interventions, is core to its long term positioning. Neuroscience, including spinal and biologics products, neuromodulation therapies and cranial technologies, adds another significant earnings stream. Meanwhile, the diabetes segment, although smaller in absolute revenue terms, has been growing faster and is where many of the company’s recent product launches are concentrated.

Read more on Medtronic

Investors and readers who want to delve deeper into Medtronic’s financial and strategic data can review the company’s investor materials and regulatory filings, which provide detailed breakdowns of segment performance, margins, cash flow and guidance.

Diabetes devices and growth

Diabetes technology has become an important growth engine for Medtronic. The company’s insulin pump systems and associated continuous glucose monitoring solutions are designed to help patients manage blood sugar levels more effectively. In fiscal 2025 third quarter, diabetes revenue of about $700 million, with roughly 10% year on year growth, underscores the demand for these products.

Medtronic has reported that new pump platforms and sensor technologies have contributed to the stronger diabetes performance. For example, more advanced algorithms for automated insulin delivery and improved connectivity features enhance user experience and clinical outcomes. The company has also highlighted geographic expansion in markets outside the United States as a driver, with increased adoption in Europe and selected emerging markets.

For Medtronic stock, the diabetes trajectory matters because it represents a segment where higher growth can offset slower moving categories and where innovation can support pricing and margin resilience. However, diabetes technology is also highly competitive, with multiple companies offering pumps, sensors and digital platforms. That competitive landscape means Medtronic must continue to invest substantially in research and development; the company has indicated R&D spending of roughly $2.8 billion for fiscal 2025, compared with around $2.6 billion in fiscal 2024, representing an increase of about 8% year on year.

Medtronic stock price and market metrics

Medtronic stock trades on the New York Stock Exchange under the ticker symbol often referenced as MDT, and its market performance reflects both broader healthcare sector dynamics and company specific news. As of 16 April 2025, Medtronic stock closed at approximately $88 per share, positioning it somewhat below a recent 52 week high near $92 but above the 52 week low around $75. That trading range gives investors a sense of how the market has valued Medtronic’s earnings trajectory, capital allocation and pipeline developments over the past year.

Based on that share price, Medtronic’s market capitalization was roughly $117 billion as of mid April 2025, placing it among the larger constituents of the S&P 500 healthcare sector. The valuation embeds expectations for continued mid single digit revenue growth, margin stability and incremental gains from diabetes and other innovation platforms. For Medtronic stock, shifts in sentiment around interest rates, healthcare reimbursement, and regulatory developments can influence how investors view that valuation level.

Dividend policy also forms part of Medtronic’s appeal for some investors. The company has signaled an annual dividend of around $2.80 per share in fiscal 2025, up from approximately $2.72 per share in the prior fiscal year, implying a year on year increase of about 3%. At a share price near $88, that dividend represents a yield close to 3.2%, though the yield naturally varies with the stock price. The steady dividend growth, even if moderate, is one reason certain income oriented investors follow Medtronic stock alongside its growth characteristics.